メディカルプレスセンター QLifePro

ニュース
添付文書
薬の臨床実感＆助言集

Refractory Multiple Myeloma

$The BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma$

The BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: for the Treatment of Relapsed Refractory Multiple Myeloma The BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent was Granted Breakthrough Therapy Designation by the

2021年02月23日

$Takeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma$

Takeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma

ヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Refractory Multiple Myeloma Takeda Receives Marketing Authorization in Canada

2016年08月08日

$U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma$

U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

バイオテクノロジーヘルスケアヘルス一般幹細胞腫瘍学臨床試験製薬　 TimeLine: FDA Grants Priority Review to Takeda's Ixazomib Refractory Multiple Myeloma

2015年09月09日

$Takeda Announces European Medicines Agency Acceptance of Ixazomib’s Marketing Authorization Application for Patients with Relapsed/Refractory Multiple Myeloma$